Across the recent three months, 7 analysts have shared their insights on Iovance Biotherapeutics (NASDAQ:IOVA), expressing a variety of opinions spanning from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $27.57, a high estimate of $32.00, and a low estimate of $10.00. Highlighting a 5.39% decrease, the current average has fallen from the…